Cerebral correlates of psychotic syndromes in neurodegenerative diseases

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 5, 2012, Pages 995-1012

  Jellinger, Kurt A ^a  

^a INSTITUTE OF CLINICAL NEUROBIOLOGY   (Austria)

Author keywords

Alzheimer's disease; Dementia; Frontotemporal dementia; Lewy body disease; Neurodegenerative disorders; Neuroimaging; Neuropathology; Psychotic and behavioural symptoms

Indexed keywords

BEHAVIOR; BRAIN; DEGENERATIVE DISEASE; FEMALE; HALLUCINATION; HUMAN; MALE; NEUROIMAGING; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOSIS; REVIEW;

BEHAVIORAL SYMPTOMS; CEREBRUM; FEMALE; HALLUCINATIONS; HUMANS; MALE; NEURODEGENERATIVE DISEASES; NEUROIMAGING; PSYCHOTIC DISORDERS;

EID: 84860346839     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01311.x     Document Type: Review

References (280)

1. Wikipedia. Dementia. 2010; accessed January 17, 2011.
2. Piccininni M, Di Carlo A, Baldereschi M, et al. Behavioral and psychological symptoms in Alzheimer's disease: frequency and relationship with duration and severity of the disease. Dement Geriatr Cogn Disord. 2005; 19: 276-81.
3. Braak H, Alafuzoff I, Arzberger T, et al. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006; 112: 389-404.
4. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82: 239-59.
5. Lopez OL, Becker JT, Sweet RA, et al. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2003; 15: 346-53.
6. Nelson PT, Braak H, Markesbery WR. Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol. 2009; 68: 1-14.
7. Forstl H, Besthorn C, Geiger-Kabisch C, et al. Psychotic features and the course of Alzheimer's disease: relationship to cognitive, electroencephalographic and computerized tomography findings. Acta Psychiatr Scand. 1993; 87: 395-9.
8. Reisberg B, Auer SR, Monteiro IM. Behavioral pathology in Alzheimer's disease (BEHAVE-AD) rating scale. Int Psychogeriatr. 1996; 8: 301-8; discussion 51-4.
9. Fernandez M, Gobartt AL, Balana M. Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment. BMC Neurol. 2010; 10: 87.
10. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996; 47: 1113-24.
11. Ballard CG, Jacoby R, Del Ser T, et al. Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. Am J Psychiatry. 2004; 161: 843-9.
12. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998; 51: 1546-54.
13. Massimo L, Powers C, Moore P, et al. Neuroanatomy of apathy and disinhibition in frontotemporal lobar degeneration. Dement Geriatr Cogn Disord. 2009; 27: 96-104.
14. Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry. 2000; 8: 29-34.
15. Chiu MJ, Chen TF, Yip PK, et al. Behavioral and psychologic symptoms in different types of dementia. J Formos Med Assoc. 2006; 105: 556-62.
16. Woodward M, Brodaty H, Boundy K, et al. Does executive impairment define a frontal variant of Alzheimer's disease? Int Psychogeriatr. 2010; 22: 1280-90.
17. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol. 2005; 4: 605-10.
18. Bozeat S, Gregory CA, Ralph MA, et al. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2000; 69: 178-86.
19. Finkel SI, Costa e Silva J, Cohen G, et al. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr. 1996; 8: 497-500.
20. Robert PH, Verhey FR, Byrne EJ, et al. Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. Eur Psychiatry. 2005; 20: 490-6.
21. Meeks TW, Ropacki SA, Jeste DV. The neurobiology of neuropsychiatric syndromes in dementia. Curr Opin Psychiatry. 2006; 19: 581-6.
22. Garre-Olmo J, Lopez-Pousa S, Vilalta-Franch J, et al. Grouping and trajectories of the neuropsychiatric symptoms in patients with Alzheimer's disease, part I: symptom clusters. J Alzheimers Dis. 2010; 22: 1157-67.
23. Aalten P, de Vugt ME, Lousberg R, et al. Behavioral problems in dementia: a factor analysis of the neuropsychiatric inventory. Dement Geriatr Cogn Disord. 2003; 15: 99-105.
24. Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry. 1989; 25: 39-48.
25. Aalten P, Verhey FR, Boziki M, et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord. 2007; 24: 457-63.
26. Cummings JL, Diaz C, Levy M, et al. Neuropsychiatric syndromes in neurodegenerative disease: frequency and significance. Semin Clin Neuropsychiatry. 1996; 1: 241-7.
27. Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry. 2005; 162: 2022-30.
28. Wilson RS, Krueger KR, Kamenetsky JM, et al. Hallucinations and mortality in Alzheimer disease. Am J Geriatr Psychiatry. 2005; 13: 984-90.
29. Casanova MF, Starkstein SE, Jellinger KA. Clinicopathological correlates of behavioral and psychological symptoms of dementia. Acta Neuropathol. 2011; doi: 10.1007/s00401-011-0821-3.
30. International Psychogeriatric Association. BPSD: introduction to behavioral and psychological symptoms of dementia. http://ipa-onlineorg/ipaonlinev3/ipaprograms/taskforces/bpsd/introasp. 2010; accessed February 24, 2011.
31. Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry. 1997; 54: 257-63.
32. Brodaty H, Draper B, Saab D, et al. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors. Int J Geriatr Psychiatry. 2001; 16: 504-12.
33. Mega MS, Cummings JL, Fiorello T, et al. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996; 46: 130-5.
34. Matsui H, Nishinaka K, Oda M, et al. Hypoperfusion of the visual pathway in parkinsonian patients with visual hallucinations. Mov Disord. 2006; 21: 2140-4.
35. Borroni B, Costanzi C, Padovani A. Genetic susceptibility to behavioural and psychological symptoms in Alzheimer disease. Curr Alzheimer Res. 2010; 7: 158-64.
36. Schneider LS, Dagerman KS. Psychosis of Alzheimer's disease: clinical characteristics and history. J Psychiatr Res. 2004; 38: 105-11.
37. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord. 2007; 22: 1061-8.
38. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci. 2010; 289: 12-7.
39. Molho ES, Factor SA. Psychosis. In: Pfeiffer RF, Bodis-Wollner I, editors. Current clinical neurology: Parkinson's disease and nonmotor dysfunction. Totowa, NJ: Humana Press; 2005: 49-74.
40. Williams DR, Poewe W. Lesions associated with visual hallucinations and psychoses. In: Halliday G, Barker RA, Rowe DB, editors. Non-dopamine lesions in Parkinson's disease. Oxford, New York: Oxford University Press; 2011: 242-60.
41. Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord. 2009; 24: 2175-86.
42. Aarsland D, Ballard C, Larsen JP, et al. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry. 2001; 16: 528-36.
43. Weintraub D, Mamikonyan E. Neuropsychiatric symptoms in Parkinson's disease dementia. In: Emre M, editor. Cognitive impairment and dementia in Parkinson's disease. Oxford, UK: Oxford University Press; 2010: 45-64.
44. Bronnick K, Aarsland D, Larsen JP. Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. Acta Psychiatr Scand. 2005; 112: 201-7.
45. Apostolova LG, Cummings JL. Neuropsychiatric features of dementia with Lewy bodies. In: O'Brien J, McKeith I, Ames D, Chiu E, editors. Dementia with Lewy bodies. London: Taylor & Francis; 2006: 73-94.
46. Byrne EJ, Lennox G, Lowe J, et al. Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry. 1989; 52: 709-17.
47. Nagahama Y, Okina T, Suzuki N, et al. Classification of psychotic symptoms in dementia with Lewy bodies. Am J Geriatr Psychiatry. 2007; 15: 961-7.
48. Perneczky R, Drzezga A, Boecker H, et al. Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations. Dement Geriatr Cogn Disord. 2008; 25: 531-8.
49. Simard M, van Reekum R, Cohen T. A review of the cognitive and behavioral symptoms in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci. 2000; 12: 425-50.
50. Okura T, Plassman BL, Steffens DC, et al. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. J Am Geriatr Soc. 2010; 58: 330-7.
51. Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000; 157: 708-14.
52. Alzheimer A. Ueber eine eigenartige Erkrankung der Hirnrinde (About a peculiar disease of the cerebral cortex). Allgem Z Psychiatr. 1907; 64: 146-8.
53. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc. 1996; 44: 1078-81.
54. Michel BF, Luciani V, Geda YE, et al. [In Alzheimer's disease, the clinical expression of behavioral and psychological signs and symptoms is early and specific of neuropathological stages]. Encephale. 2010; 36: 314-25.
55. Gülden W. Über anatomische Befunde und klinische Verlaufsformen bei senilen Psychosen (About anatomical findings and clinical types of senile psychoses). Univ. Hamburg Medical School: Thesis, 1946.
56. Schreinzer D, Ballaban T, Brannath W, et al. Components of behavioral pathology in dementia. Int J Geriatr Psychiatry. 2005; 20: 137-45.
57. Rosen J, Zubenko GS. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol Psychiatry. 1991; 29: 224-32.
58. Ballard C, Holmes C, McKeith I, et al. Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer's disease. Am J Psychiatry. 1999; 156: 1039-45.
59. Engelborghs S, Maertens K, Marien P, et al. Behavioural and neuropsychological correlates of frontal lobe features in dementia. Psychol Med. 2006; 36: 1173-82.
60. Bassiony MM, Lyketsos CG. Delusions and hallucinations in Alzheimer's disease: review of the brain decade. Psychosomatics. 2003; 44: 388-401.
61. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain. 2002; 125: 391-403.
62. Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol. 2000; 48: 868-76.
63. Ostling S, Gustafson D, Blennow K, et al. Psychotic symptoms in a population-based sample of 85-year-old individuals with dementia. J Geriatr Psychiatry Neurol. 2010.
64. Ostling S, Borjesson-Hanson A, Skoog I. Psychotic symptoms and paranoid ideation in a population-based sample of 95-year-olds. Am J Geriatr Psychiatry. 2007; 15: 999-1004.
65. Forstl H, Burns A, Levy R, et al. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease. Br J Psychiatry. 1994; 165: 53-9.
66. Wilkosz PA, Miyahara S, Lopez OL, et al. Prediction of psychosis onset in Alzheimer disease: the role of cognitive impairment, depressive symptoms, and further evidence for psychosis subtypes. Am J Geriatr Psychiatry. 2006; 14: 352-60.
67. Weamer EA, Emanuel JE, Varon D, et al. The relationship of excess cognitive impairment in MCI and early Alzheimer's disease to the subsequent emergence of psychosis. Int Psychogeriatr. 2009; 21: 78-85.
68. Assal F, Cummings JL. Neuropsychiatric symptoms in the dementias. Curr Opin Neurol. 2002; 15: 445-50.
69. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. IV: disorders of behaviour. Br J Psychiatry. 1990; 157: 86-94.
70. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. III: disorders of mood. Br J Psychiatry. 1990; 157: 81-6, 92-4.
71. Tariot PN, Mack JL, Patterson MB, et al. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's Disease. Am J Psychiatry. 1995; 152: 1349-57.
72. Rubin EH, Drevets WC, Burke WJ. The nature of psychotic symptoms in senile dementia of the Alzheimer type. J Geriatr Psychiatry Neurol. 1988; 1: 16-20.
73. Ballard CG, Bannister CL, Patel A, et al. Classification of psychotic symptoms in dementia sufferers. Acta Psychiatr Scand. 1995; 92: 63-8.
74. Hwang JP, Tsai SJ, Yang CH, et al. Persecutory delusions in dementia. J Clin Psychiatry. 1999; 60: 550-3.
75. Perez-Madrinan G, Cook SE, Saxton JA, et al. Alzheimer disease with psychosis: excess cognitive impairment is restricted to the misidentification subtype. Am J Geriatr Psychiatry. 2004; 12: 449-56.
76. Capitani E, Francescani A, Spinnler H. Are hallucinations and extrapyramidal signs associated with a steeper cognitive decline in degenerative dementia patients? Neurol Sci. 2007; 28: 245-50.
77. Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol. 2005; 62: 1601-8.
78. Stern Y, Mayeux R, Sano M, et al. Predictors of disease course in patients with probable Alzheimer's disease. Neurology. 1987; 37: 1649-53.
79. Sweet RA, Nimgaonkar VL, Devlin B, et al. Psychotic symptoms in Alzheimer disease: evidence for a distinct phenotype. Mol Psychiatry. 2003; 8: 383-92.
80. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry. 1987; 48: 9-15.
81. Ballard CG, Chithiramohan RN, Bannister C, et al. Paranoid features in the elderly with dementia. Int J Geriatr Psychiatry. 1991; 6: 155-7.
82. Chen JY, Stern Y, Sano M, et al. Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer's disease. Arch Neurol. 1991; 48: 1141-3.
83. Gilley DW, Whalen ME, Wilson RS, et al. Hallucinations and associated factors in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1991; 3: 371-6.
84. Deutsch LH, Bylsma FW, Rovner BW, et al. Psychosis and physical aggression in probable Alzheimer's disease. Am J Psychiatry. 1991; 148: 1159-63.
85. Lopez OL, Becker JT, Brenner RP, et al. Alzheimer's disease with delusions and hallucinations: neuropsychological and electroencephalographic correlates. Neurology. 1991; 41: 906-12.
86. Gilley DW, Wilson RS, Beckett LA, et al. Psychotic symptoms and physically aggressive behavior in Alzheimer's disease. J Am Geriatr Soc. 1997; 45: 1074-9.
87. Sweet RA, Nimgaonkar VL, Devlin B, et al. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology. 2002; 58: 907-11.
88. Hollingworth P, Hamshere ML, Holmans PA, et al. Increased familial risk and genomewide significant linkage for Alzheimer's disease with psychosis. Am J Med Genet B Neuropsychiatr Genet. 2007; 144B: 841-8.
89. Bacanu SA, Devlin B, Chowdari KV, et al. Heritability of psychosis in Alzheimer disease. Am J Geriatr Psychiatry. 2005; 13: 624-7.
90. Del Prete M, Spaccavento S, Craca A, et al. Neuropsychiatric symptoms and the APOE genotype in Alzheimer's disease. Neurol Sci. 2009; 30: 367-73.
91. Go RC, Perry RT, Wiener H, et al. Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses. Am J Med Genet B Neuropsychiatr Genet. 2005; 139B: 28-32.
92. Middle F, Pritchard AL, Handoko H, et al. No association between neuregulin 1 and psychotic symptoms in Alzheimer's disease patients. J Alzheimers Dis. 2010; 20: 561-7.
93. Avramopoulos D, Fallin MD, Bassett SS. Linkage to chromosome 14q in Alzheimer's disease (AD) patients without psychotic symptoms. Am J Med Genet B Neuropsychiatr Genet. 2005; 132B: 9-13.
94. Pritchard AL, Pritchard CW, Bentham P, et al. Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients. Dement Geriatr Cogn Disord. 2007; 24: 201-6.
95. Assal F, Alarcon M, Solomon EC, et al. Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease. Arch Neurol. 2004; 61: 1249-53.
96. Craig D, Donnelly C, Hart D, et al. Analysis of the 5HT-2A T102C receptor polymorphism and psychotic symptoms in Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet. 2007; 144B: 126-8.
97. Ramanathan S, Glatt SJ. Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis. Am J Geriatr Psychiatry. 2009; 17: 839-46.
98. Pritchard AL, Ratcliffe L, Sorour E, et al. Investigation of dopamine receptors in susceptibility to behavioural and psychological symptoms in Alzheimer's disease. Int J Geriatr Psychiatry. 2009; 24: 1020-5.
99. Sweet RA, Nimgaonkar VL, Kamboh MI, et al. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol. 1998; 55: 1335-40.
100. Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry. 2006; 60: 141-51.
101. Demichele-Sweet MA, Klei L, Devlin B, et al. No association of psychosis in Alzheimer disease with neurodegenerative pathway genes. Neurobiol Aging. 2010; online 2010-11-17: doi:10.1016/j.neurobiolaging.2010.10.003.
102. DeMichele-Sweet MA, Sweet RA. Genetics of psychosis in Alzheimer's disease: a review. J Alzheimers Dis. 2010; 19: 761-80.
103. Kotrla KJ, Chacko RC, Harper RG, et al. SPECT findings on psychosis in Alzheimer's disease. Am J Psychiatry. 1995; 152: 1470-5.
104. Sultzer DL, Mahler ME, Mandelkern MA, et al. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1995; 7: 476-84.
105. Pietrini P, Furey ML, Graff-Radford N, et al. Preferential metabolic involvement of visual cortical areas in a subtype of Alzheimer's disease: clinical implications. Am J Psychiatry. 1996; 153: 1261-8.
106. Mega MS, Lee L, Dinov ID, et al. Cerebral correlates of psychotic symptoms in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2000; 69: 167-71.
107. Moran EK, Becker JA, Satlin A, et al. Psychosis of Alzheimer's disease: gender differences in regional perfusion. Neurobiol Aging. 2008; 29: 1218-25.
108. Lanctot KL, Herrmann N, Nadkarni NK, et al. Medial temporal hypoperfusion and aggression in Alzheimer disease. Arch Neurol. 2004; 61: 1731-7.
109. Nakano S, Yamashita F, Matsuda H, et al. Relationship between delusions and regional cerebral blood flow in Alzheimer's disease. Dement Geriatr Cogn Disord. 2006; 21: 16-21.
110. Staff RT, Venneri A, Gemmell HG, et al. HMPAO SPECT imaging of Alzheimer's disease patients with similar content-specific autobiographic delusion: comparison using statistical parametric mapping. J Nucl Med. 2000; 41: 1451-5.
111. Sultzer DL, Brown CV, Mandelkern MA, et al. Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease. Am J Psychiatry. 2003; 160: 341-9.
112. Geroldi C, Bresciani L, Zanetti O, et al. Regional brain atrophy in patients with mild Alzheimer's disease and delusions. Int Psychogeriatr. 2002; 14: 365-78.
113. Holroyd S, Shepherd ML, Downs JH3rd,. Occipital atrophy is associated with visual hallucinations in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 2000; 12: 25-8.
114. Bruen PD, McGeown WJ, Shanks MF, et al. Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease. Brain. 2008; 131: 2455-63.
115. Serra L, Perri R, Cercignani M, et al. Are the behavioral symptoms of Alzheimer's disease directly associated with neurodegeneration? J Alzheimers Dis. 2010; 21: 627-39.
116. Lee DY, Choo IH, Kim KW, et al. White matter changes associated with psychotic symptoms in Alzheimer's disease patients. J Neuropsychiatry Clin Neurosci. 2006; 18: 191-8.
117. Lin SH, Yu CY, Pai MC. The occipital white matter lesions in Alzheimer's disease patients with visual hallucinations. Clin Imaging. 2006; 30: 388-93.
118. Sweet RA, Panchalingam K, Pettegrew JW, et al. Psychosis in Alzheimer disease: postmortem magnetic resonance spectroscopy evidence of excess neuronal and membrane phospholipid pathology. Neurobiol Aging. 2002; 23: 547-53.
119. Zubenko GS, Moossy J, Martinez AJ, et al. Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol. 1991; 48: 619-24.
120. Lanari A, Amenta F, Silvestrelli G, et al. Neurotransmitter deficits in behavioural and psychological symptoms of Alzheimer's disease. Mech Ageing Dev. 2006; 127: 158-65.
121. Weinshenker D. Functional consequences of locus coeruleus degeneration in Alzheimer's disease. Curr Alzheimer Res. 2008; 5: 342-5.
122. Perry EK, Kerwin J, Perry RH, et al. Visual hallucinations and the cholinergic system in dementia (letter). J Neurol Neurosurg Psychiatry. 1990; 53: 88.
123. Perry EK, Marshall E, Kerwin J, et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem. 1990; 55: 1454-6.
124. McShane R, Gedling K, Reading M, et al. Prospective study of relations between cortical Lewy bodies, poor eyesight, and hallucinations in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1995; 59: 185-8.
125. Cummings JL. Organic delusions: phenomenology, anatomical correlations, and review. Br J Psychiatry. 1985; 146: 184-97.
126. Le Ber I, Marie RM, Chabot B, et al. Neuropsychological and 18FDG-PET studies in a family with idiopathic basal ganglia calcifications. J Neurol Sci. 2007; 258: 115-22.
127. Staton RD, Brumback RA, Wilson H. Reduplicative paramnesia: a disconnection syndrome of memory. Cortex. 1982; 18: 23-35.
128. Lai MK, Chen CP, Hope T, et al. Hippocampal neurofibrillary tangle changes and aggressive behaviour in dementia. Neuroreport. 2010; 21: 1111-5.
129. Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry. 2006; 63: 161-7.
130. Guimaraes HC, Levy R, Teixeira AL, et al. Neurobiology of apathy in Alzheimer's disease. Arq Neuropsiquiatr. 2008; 66: 436-43.
131. Fenelon G. Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr. 2008; 13: 18-25.
132. Eng ML, Welty TE. Management of hallucinations and psychosis in Parkinson's disease. Am J Geriatr Pharmacother. 2010; 8: 316-30.
133. Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006; 66: 93-8.
134. Fernandez HH, Aarsland D, Fenelon G, et al. Scales to assess psychosis in Parkinson's disease: critique and recommendations. Mov Disord. 2008; 23: 484-500.
135. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, et al. Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord. 2008; 23: 1889-96.
136. Fenelon G, Soulas T, Zenasni F, et al. The changing face of Parkinson's disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010; 25: 755-9.
137. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2001; 70: 734-8.
138. Fenelon G, Thobois S, Bonnet AM, et al. Tactile hallucinations in Parkinson's disease. J Neurol. 2002; 249: 1699-703.
139. Goetz CG, Wuu J, Curgian L, et al. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006; 21: 267-70.
140. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998; 64: 533-5.
141. Tousi B, Frankel M. Olfactory and visual hallucinations in Parkinson's disease. Parkinsonism Relat Disord. 2004; 10: 253-4.
142. Fenelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain. 2000; 123: 733-45.
143. Mosimann UP, Rowan EN, Partington CE, et al. Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry. 2006; 14: 153-60.
144. Onofrj M, Thomas A, Bonanni L. New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins. Expert Rev Neurother. 2007; 7: 1731-50.
145. Kurita A, Murakami M, Takagi S, et al. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disord. 2010; 25: 167-71.
146. Meppelink AM, de Jong BM, Renken R, et al. Impaired visual processing preceding image recognition in Parkinson's disease patients with visual hallucinations. Brain. 2009; 132: 2980-93.
147. Aarsland D, Larsen JP. Diagnosis and treatment of hallucinations and delusions in Parkinson's disease. In: Bédard M-A, Agid Y, Chouinard S, Fahn S, Korczyn AD, Lespérance P, editors. Mental and behavioral dysfunctions in movement disorders. Totowa, NJ: Humana Press Inc.; 2003: pp. 369-82.
148. Verbaan D, van Rooden SM, Visser M, et al. Psychotic and compulsive symptoms in Parkinson's disease. Mov Disord. 2009; 24: 738-44.
149. Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology. 2004; 63: 293-300.
150. Wolters E. PD-related psychosis: pathophysiology with therapeutical strategies. J Neural Transm Suppl. 2006; 71: 31-7.
151. Lauterbach EC. The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr Clin North Am. 2004; 27: 801-25.
152. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999; 67: 492-6.
153. Williams-Gray CH, Foltynie T, Lewis SJ, et al. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs. 2006; 20: 477-505.
154. Goetz CG, Ouyang B, Negron A, et al. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010; 75: 1773-9.
155. Sanchez-Ramos JR, Ortoll R, et al. Visual hallucinations associated with Parkinson disease. Arch Neurol. 1996; 53: 1265-8.
156. Imamura K, Wada-Isoe K, Kitayama M, et al. Executive dysfunction in non-demented Parkinson's disease patients with hallucinations. Acta Neurol Scand. 2008; 117: 255-9.
157. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol. 2010; 67: 996-1001.
158. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003; 60: 1756-61.
159. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology. 2010; 75: 1270-6.
160. Ballard C, Aarsland D. Spectrum of Lewy body dementias: relationship of Parkinson's disease dementia to dementia with Lewy bodies. In: Emre M, editor. Cognitive impairment and dementia in Parkinson's disease. Oxford, UK: Oxford University Press; 2010: 199-214.
161. Borroni B, Agosti C, Padovani A. Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment. Arch Gerontol Geriatr. 2008; 46: 101-6.
162. Klatka LA, Louis ED, Schiffer RB. Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups. Neurology. 1996; 47: 1148-52.
163. Del Ser T, Hachinski V, Merskey H, et al. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord. 2001; 15: 31-44.
164. Ala TA, Yang KH, Sung JH, et al. Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer's disease at presentation: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1997; 62: 16-21.
165. McKeith IG, Ballard CG, Perry RH, et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology. 2000; 54: 1050-8.
166. Tiraboschi P, Salmon DP, Hansen LA, et al. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? Brain. 2006; 129: 729-35.
167. Ballard CG, O'Brien JT, Swann AG, et al. The natural history of psychosis and depression in dementia with Lewy bodies and Alzheimer's disease: persistence and new cases over 1 year of follow-up. J Clin Psychiatry. 2001; 62: 46-9.
168. Ballard C, Lowery K, Harrison R, et al. Noncognitive symptoms in Lewy body dementia. In: Perry EK, McKeith IG, Perry EK, editors. Dementia with Lewy bodies. 1st ed. Cambridge, UK: Cambridge Univ. Press; 1996: 67-84.
169. Stavitsky K, Brickman AM, Scarmeas N, et al. The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease. Arch Neurol. 2006; 63: 1450-6.
170. Mori E, Shimomura T, Fujimori M, et al. Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol. 2000; 57: 489-93.
171. Mosimann UP, Mather G, Wesnes KA, et al. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 2004; 63: 2091-6.
172. Oinas M, Polvikoski T, Sulkava R, et al. Neuropathologic findings of dementia with Lewy bodies (DLB) in a population-based Vantaa 85+ study. J Alzheimers Dis. 2009; 18: 677-89.
173. Boecker H, Ceballos-Baumann AO, Volk D, et al. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol. 2007; 64: 984-8.
174. Okada K, Suyama N, Oguro H, et al. Medication-induced hallucination and cerebral blood flow in Parkinson's disease. J Neurol. 1999; 246: 365-8.
175. Nagano-Saito A, Washimi Y, Arahata Y, et al. Visual hallucination in Parkinson's disease with FDG PET. Mov Disord. 2004; 19: 801-6.
176. Oishi N, Udaka F, Kameyama M, et al. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology. 2005; 65: 1708-15.
177. Colloby S, O'Brien J. Functional imaging in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004; 17: 158-63.
178. O'Brien JT, Firbank MJ, Mosimann UP, et al. Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies. Psychiatry Res. 2005; 139: 79-88.
179. Lobotesis K, Fenwick JD, Phipps A, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology. 2001; 56: 643-9.
180. Colloby SJ, Fenwick JD, Williams ED, et al. A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging. 2002; 29: 615-22.
181. Donnemiller E, Heilmann J, Wenning GK, et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med. 1997; 24: 320-5.
182. Imamura T, Ishii K, Hirono N, et al. Occipital glucose metabolism in dementia with Lewy bodies with and without Parkinsonism: a study using positron emission tomography. Dement Geriatr Cogn Disord. 2001; 12: 194-7.
183. Pasquier J, Michel BF, Brenot-Rossi I, et al. Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2002; 29: 1342-8.
184. Imamura T, Ishii K, Hirono N, et al. Visual hallucinations and regional cerebral metabolism in dementia with Lewy bodies (DLB). Neuroreport. 1999; 10: 1903-7.
185. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology. 2004; 63: 1409-16.
186. Nagahama Y, Okina T, Suzuki N, et al. Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain. 2010; 133: 557-67.
187. Middelkoop HA, van der Flier WM, Burton EJ, et al. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology. 2001; 57: 2117-20.
188. Sanchez-Castaneda C, Rene R, Ramirez-Ruiz B, et al. Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia. Mov Disord. 2010; 25: 615-22.
189. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, et al. Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia. J Neurol. 2008; 255: 1324-31.
190. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, et al. Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry. 2010; 81: 650-7.
191. Teaktong T, Piggott MA, McKeith IG, et al. Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. Behav Brain Res. 2005; 161: 299-305.
192. Burkhardt CR, Filley CM, Kleinschmidt-DeMasters BK, et al. Diffuse Lewy body disease and progressive dementia. Neurology. 1988; 38: 1520-8.
193. Gomez-Tortosa E, Ingraham AO, Irizarry MC, et al. Dementia with Lewy bodies. J Am Geriatr Soc. 1998; 46: 1449-58.
194. Kalaitzakis ME, Christian LM, Moran LB, et al. Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. Parkinsonism Relat Disord. 2009; 15: 196-204.
195. Harding AJ, Halliday GM. Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathol. 2001; 102: 355-63.
196. Papapetropoulos S, Lieberman A, Gonzalez J, et al. Can Alzheimer's type pathology influence the clinical phenotype of Parkinson's disease? Acta Neurol Scand. 2005; 111: 353-9.
197. Camicioli R, Rajput A, Rajput M, et al. Apolipoprotein E epsilon4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: relationship to dementia and hallucinations. Mov Disord. 2005; 20: 989-94.
198. McShane R, Keene J, Gedling K, et al. Hallucinations, cortical Lewy body pathology, cognitive function and neuroleptics use in dementia. In: Perry EK, McKeith IG, Perry EK, editors. Dementia with Lewy bodies. 1st ed. Cambridge, UK: Cambridge Univ. Press; 1996: p. 85-98.
199. Gomez-Tortosa E, Newell K, Irizarry MC, et al. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology. 1999; 53: 1284-91.
200. Kempster PA, O'Sullivan SS, Holton JL, et al. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain. 2010; 133: 1755-62.
201. Brooks D, Halliday GM. Intralaminar nuclei of the thalamus in Lewy body diseases. Brain Res Bull. 2009; 78: 97-104.
202. Halliday GM. Thalamic changes in Parkinson's disease. Parkinsonism Relat Disord. 2009; 15: S152-5.
203. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65: 1863-72.
204. Tsuang DW, Riekse RG, Purganan KM, et al. Lewy body pathology in late-onset familial Alzheimer's disease: a clinicopathological case series. J Alzheimers Dis. 2006; 9: 235-42.
205. Hansen L, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity. Neurology. 1990; 40: 1-8.
206. Hansen LA. The Lewy body variant of Alzheimer disease. J Neural Transm Suppl. 1997; 51: 83-93.
207. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: clinical and pathological implications. Arch Neurol. 2001; 58: 186-90.
208. Tsuang D, Larson EB, Bolen E, et al. Visual hallucinations in dementia: a prospective community-based study with autopsy. Am J Geriatr Psychiatry. 2009; 17: 317-23.
209. Merdes AR, Hansen LA, Jeste DV, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003; 60: 1586-90.
210. Caine ED, Shoulson I. Psychiatric syndromes in Huntington's disease. Am J Psychiatry. 1983; 140: 728-33.
211. Mendez MF. Huntington's disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med. 1994; 24: 189-208.
212. Tsuang D, Almqvist EW, Lipe H, et al. Familial aggregation of psychotic symptoms in Huntington's disease. Am J Psychiatry. 2000; 157: 1955-9.
213. Paulsen JS, Ready RE, Hamilton JM, et al. Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry. 2001; 71: 310-4.
214. Guttman M, Alpay M, Chouinard S, et al. Clinical management of psychosis and mood disorders in Huntington's disease. In: BÈdard M-A, Agid Y, Chouinard S, Fahn S, Korczyn AD, editors. Mental and behavioral dysfunction in movement disorders. Totowa, NJ: Humana Press; 2003: 409-26.
215. Julien CL, Thompson JC, Wild S, et al. Psychiatric disorders in preclinical Huntington's disease. J Neurol Neurosurg Psychiatry. 2007; 78: 939-43.
216. Marshall J, White K, Weaver M, et al. Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol. 2007; 64: 116-21.
217. van Duijn E, Kingma EM, Timman R, et al. Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington's disease compared with mutation-negative first-degree relatives. J Clin Psychiatry. 2008; 69: 1804-10.
218. Duff K, Paulsen JS, Beglinger LJ, et al. Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry. 2007; 62: 1341-6.
219. Zappacosta B, Monza D, Meoni C, et al. Psychiatric symptoms do not correlate with cognitive decline, motor symptoms, or CAG repeat length in Huntington's disease. Arch Neurol. 1996; 53: 493-7.
220. Rosenblatt A. Neuropsychiatry of Huntington's disease. Dialogues Clin Neurosci. 2007; 9: 191-7.
221. Benarroch EE. The midline and intralaminar thalamic nuclei: anatomic and functional specificity and implications in neurologic disease. Neurology. 2008; 71: 944-9.
222. Joel D. Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease. Mov Disord. 2001; 16: 407-23.
223. Mendez MF, Shapira JS, Woods RJ, et al. Psychotic symptoms in frontotemporal dementia: prevalence and review. Dement Geriatr Cogn Disord. 2008; 25: 206-11.
224. Larner AJ. Delusion of pregnancy in frontotemporal lobar degeneration with motor neurone disease (FTLD/MND). Behav Neurol. 2008; 19: 199-200.
225. Liscic RM, Kogoj A. Social behaviour versus psychiatric features of frontotemporal dementia - Clinical report of two cases. Psychiatr Danub. 2010; 22: 179-82.
226. Mendez MF, Lauterbach EC, Sampson SM. An evidence-based review of the psychopathology of frontotemporal dementia: a report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci. 2008; 20: 130-49.
227. Reischle E, Sturm K, Schuierer G, et al. A case of schizophreniform disorder in frontotemporal dementia (FTD). Psychiatr Prax. 2003; 30: S78-82.
228. Reischle E, Sturm K, Schuierer G, et al. Frontotemporal dementia presenting as acute late onset schizophrenia. Psychiatr Prax. 2003; 30: 78-82.
229. Kerssens CJ, Pijnenburg YA, Schouws S, et al. The development of psychotic symptoms in later life: late-onset schizophrenia or frontotemporal dementia? A case study. Tijdschr Psychiatr. 2006; 48: 739-44.
230. Lillo P, Garcin B, Hornberger M, et al. Neurobehavioral features in frontotemporal dementia with amyotrophic lateral sclerosis. Arch Neurol. 2010; 67: 826-30.
231. Velakoulis D, Walterfang M, Mocellin R, et al. Frontotemporal dementia presenting as schizophrenia-like psychosis in young people: clinicopathological series and review of cases. Br J Psychiatry. 2009; 194: 298-305.
232. Tartaglia MC, Kertesz A, Ang LC. Delusions and hallucinations in frontotemporal dementia: a clinicopathologic case report. Cogn Behav Neurol. 2008; 21: 107-10.
233. Loy CT, Kril JJ, Trollor JN, et al. The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol. 2010; 6: 175-9.
234. Claassen DO, Parisi JE, Giannini C, et al. Frontotemporal dementia mimicking dementia with Lewy bodies. Cogn Behav Neurol. 2008; 21: 157-63.
235. Roeber S, Mackenzie IR, Kretzschmar HA, et al. TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol. 2008; 116: 147-57.
236. Neumann M, Rademakers R, Roeber S, et al. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009; 132: 2922-31.
237. Mackenzie IR, Munoz DG, Kusaka H, et al. Distinct pathological subtypes of FTLD-FUS. Acta Neuropathol. 2011; 121: 207-18.
238. Howland RH. Schizophrenia and amyotrophic lateral sclerosis. Compr Psychiatry. 1990; 31: 327-36.
239. Thiel A, Pilichowska ME, Hemmerlein B, et al. Dementia and psychotic symptoms in amyotrophic lateral sclerosis. Nervenarzt. 1993; 64: 618-22.
240. Dervaux A, Laine H. [The psychiatric forms of Creutzfeldt-Jakob disease]. Presse Med. 2003; 32: 1466-8.
241. Wall CA, Rummans TA, Aksamit AJ, et al. Psychiatric manifestations of Creutzfeldt-Jakob disease: a 25-year analysis. J Neuropsychiatry Clin Neurosci. 2005; 17: 489-95.
242. Dunn NR, Alfonso CA, Young RA, et al. Creutzfeldt-Jakob disease appearing as paranoid psychosis (Letter to the Editor). Am J Psychiatry. 1999; 156: 2016-7.
243. Stevens EM, Lament R. Psychiatric presentation of Jakob-Creutzfeldt disease. J Clin Psychiatry. 1979; 40: 445-6.
244. Jardri R, DiPaola C, Lajugie C, et al. Depressive disorder with psychotic symptoms as psychiatric presentation of sporadic Creutzfeldt-Jakob disease: a case report. Gen Hosp Psychiatry. 2006; 28: 452-4.
245. Zeidler M, Johnstone EC, Bamber RW, et al. New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet. 1997; 350: 908-10.
246. Dervaux A, Vicart S, Lopes F, et al. Psychiatric manifestations of a new variant of Creutzfeldt-Jakob disease. Apropos of a case. Encephale. 2001; 27: 194-7.
247. Martindale JL, Geschwind MD, Miller BL. Psychiatric and neuroimaging findings in Creutzfeldt-Jakob disease. Curr Psychiatry Rep. 2003; 5: 43-6.
248. Spalletta G, Baldinetti F, Buccione I, et al. Cognition and behaviour are independent and heterogeneous dimensions in Alzheimer's disease. J Neurol. 2004; 251: 688-95.
249. Senanarong V, Cummings JL, Fairbanks L, et al. Agitation in Alzheimer's disease is a manifestation of frontal lobe dysfunction. Dement Geriatr Cogn Disord. 2004; 17: 14-20.
250. Zamboni G, Huey ED, Krueger F, et al. Apathy and disinhibition in frontotemporal dementia: insights into their neural correlates. Neurology. 2008; 71: 736-42.
251. Fischer C, Bozanovic R, Atkins JH, et al. Treatment of delusions in dementia with Lewy bodies - response to pharmacotherapy. Dement Geriatr Cogn Disord. 2007; 23: 307-11.
252. Banerjee AK, Falkai PG, Savidge M. Visual hallucinations in the elderly associated with the use of levodopa. Postgrad Med J. 1989; 65: 358-61.
253. Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov Disord. 2007; 22: S351-7.
254. Goetz CG. New developments in depression, anxiety, compulsiveness, and hallucinations in Parkinson's disease. Mov Disord. 2010; 25: S104-9.
255. Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology. 1998; 50: 515-7.
256. Rabey JM. Hallucinations and psychosis in Parkinson's disease. Parkinsonism Relat Disord. 2009; 15: S105-10.
257. Court JA, Ballard CG, Piggott MA, et al. Visual hallucinations are associated with lower alpha bungarotoxin binding in dementia with Lewy bodies. Pharmacol Biochem Behav. 2001; 70: 571-9.
258. Cheng AV, Ferrier IN, Morris CM, et al. Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer's and Parkinson's diseases. J Neurol Sci. 1991; 106: 50-5.
259. Kurita A, Murakami M, Takagi S, et al. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disord. 2010; 25: 167-71.
260. Mori T, Ikeda M, Fukuhara R, et al. Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology. 2006; 66: 935-7.
261. Diederich NJ, Fenelon G, Stebbins G, et al. Hallucinations in Parkinson disease. Nat Rev Neurol. 2009; 5: 331-42.
262. Goetz CG, Burke PF, Leurgans S, et al. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol. 2001; 58: 209-13.
263. Piggott MA, Marshall EF, Thomas N, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain. 1999; 122: 1449-68.
264. Sweet RA, Hamilton RL, Healy MT, et al. Alterations of striatal dopamine receptor binding in Alzheimer disease are associated with Lewy body pathology and antemortem psychosis. Arch Neurol. 2001; 58: 466-72.
265. Langlais PJ, Thal L, Hansen L, et al. Neurotransmitters in basal ganglia and cortex of Alzheimer's disease with and without Lewy bodies. Neurology. 1993; 43: 1927-34.
266. Kiferle L, Ceravolo R, Petrozzi L, et al. Visual hallucinations in Parkinson's disease are not influenced by polymorphisms of serotonin 5-HT2A receptor and transporter genes. Neurosci Lett. 2007; 422: 228-31.
267. Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol. 2010; 67: 416-21.
268. Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007; 69: 2197-204.
269. Fernando MS, Ince PG. Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci. 2004; 226: 13-7.
270. Kovacs GG, Alafuzoff I, Al-Sarraj S, et al. Mixed brain pathologies in dementia: the BrainNet Europe consortium experience. Dement Geriatr Cogn Disord. 2008; 26: 343-50.
271. Klugman A, Marshall J, Tabet N. Impact of cerebrovascular pathology on behavioural and neuropsychiatric symptoms in patients with Alzheimer's dementia: findings from a retrospective, naturalistic study. Int J Clin Pract. 2009; 63: 1024-30.
272. Zekry D, Hauw JJ, Gold G. Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc. 2002; 50: 1431-8.
273. Jellinger KA. Prevalence and impact of cerebrovascular lesions in Alzheimer and Lewy body diseases. Neurodegener Dis. 2010; 7: 112-5.
274. Woodward M, Mackenzie IR, Feldman H. High prevalence of multiple brain pathologies in demenmtia (abs.). Alzheimer's & Dem. 2006; 2: S426.
275. Jellinger KA. The enigma of mixed dementia. Alzheimers Dement. 2007; 3: 40-53.
276. Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. J Neurol Sci. 2007; 257: 80-7.
277. Jellinger KA, Attems J. Prevalence of dementia disorders in the oldest-old: an autopsy study. Acta Neuropathol. 2010; 119: 421-33.
278. Savva GM, Zaccai J, Matthews FE, et al. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry. 2009; 194: 212-9.
279. Spalletta G, Musicco M, Padovani A, et al. Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. Am J Geriatr Psychiatry. 2010; 18: 1026-35.
280. Snow RE, Arnold SE. Psychosis in neurodegenerative disease. Semin Clin Neuropsychiatry. 1996; 1: 282-93.